Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 119 of 6351
-
Can a chemo boost outsmart lingering colon cancer cells?
Disease control Recruiting nowThis study is a prospective, open-label, randomized phase 3 clinical trial. It aims to investigate if the early introduction of intensified chemotherapy (3 months of modified FOLFIRINOX) improves the 3-year disease-free survival rate compared to standard treatment (FOLFOX/CAPOX f…
Phase 3 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New shot shows promise for tough eczema in major trial
Disease control CompletedThe co-primary objectives of the study are to: * Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD). * Evaluate the efficacy of rocatinlimab compared with placebo at We…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug targets 'Silent' heart risk in 7,000-Patient trial
Disease control OngoingThe primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease …
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug aims to save lives in severe viral lung infections
Disease control Recruiting nowThe purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill could outperform chemo for rare lung cancer
Disease control OngoingThis is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not receiv…
Phase 3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could flickering lights and tones help fight Alzheimer's? major trial underway
Disease control CompletedThis is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device, Spectris™ AD, for 60 minutes daily for approximately …
Sponsor: Cognito Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC
-
Lyme vaccine passes safety check in 3,500 kids
Vaccine CompletedThis study is to understand if the study vaccine (called VLA15) is safe in healthy children. We are looking for children who: * are healthy * are age 5 through 17 * have not been diagnosed with any form of Lyme disease in the past * have not received any vaccines for Lyme disea…
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:30 UTC
-
Artificial heart offers hope for transplant candidates
Disease control OngoingThe objective of this clinical investigation is to evaluate the efficacy and the safety of the Carmat Total Artificial Heart for the treatment of refractory advanced heart failure in transplant eligible patients.
Sponsor: Carmat SAS • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for aggressive breast cancer: combo therapy targets leftover disease after surgery
Disease control Recruiting nowThe goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizum…
Phase 3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC
-
New drug cocktail aims to control advanced breast cancer
Disease control OngoingThis is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK…
Phase 3 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug aims to cure hepatitis b without lifelong pills
Disease control CompletedThis study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 st…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug aims to free hepatitis b patients from daily pills
Disease control CompletedThis study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 st…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Zapping heart trouble without surgery: new trial tests Non-Invasive radiation
Disease control Recruiting nowThis study compares two arms - the current standard of care catheter ablation for Ventricular Tachycardia compared to stereotactic radiotherapy to non-invasively ablate ventricular tachycardia using a novel non-invasive ECG based body surface mapping technology. This allows inves…
Phase 3 • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New study aims to shield vulnerable groups from COVID-19
Vaccine OngoingDespite the greater risk of adverse COVID-19 outcomes, antibody and cell-mediated immune responses to COVID-19 vaccines vary amongst immunocompromised (IC) people and are poorly defined. IC hosts were largely excluded from the COVID-19 vaccine registration trials, though many cou…
Phase 3 • Sponsor: Monash University • Aim: Vaccine
Last updated Jun 27, 2026 07:53 UTC
-
Your genes could guide safer drug doses
Prevention OngoingIn PT@LUMC 2000 patients will be randomized between a PGx-guided dosing group and a standard of care group. The patients will be followed for one year in which they will be asked to report adverse drug reactions at one, three, six and twelve months.
Sponsor: Leiden University Medical Center • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Stem cells injected into brain to fight Parkinson's
Disease control OngoingParkinson's disease (PD) occurs when an area of the brain begins to lose nerve cells that produce a chemical called dopamine. Dopamine is an important chemical, and one of its functions is that it helps to regulate body movement. The loss of these nerve cells leads to a reduction…
Phase 1 • Sponsor: Region Skane • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Personalized vaccine aims to train immune system against cancer
Vaccine By invitation onlyA Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Phase 1/2 • Sponsor: Jaime Leandro Foundation for Therapeutic Cancer Vaccines • Aim: Vaccine
Last updated Jun 27, 2026 08:11 UTC
-
Could this vaccine stop the superbug gonorrhea?
Vaccine CompletedThe aim of this first time in human proof of concept (FTiH-PoC) study was to evaluate safety and reactogenicity, to demonstrate efficacy and to explore immunogenicity of GlaxoSmithKline's (GSK) Neisseria gonorrhoeae generalized modules for membrane antigens (GMMA) (NgG) investiga…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough breast cancer: drug combo targets remaining disease after surgery
Disease control OngoingThis is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary ly…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Trikafta's long-term safety tested in cystic fibrosis patients with rare mutations
Disease control OngoingThis study will evaluate the long-term safety, efficacy and pharmacodynamics of ELX/TEZ/IVA in participants with cystic fibrosis (CF) with at least 1 non-F508del ELX/TEZ/IVA-responsive CF transmembrane conductance regulator (CFTR) gene mutation.
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC